Oxford Biomedica, Santen enter retinal disease R&D alliance
Inherited retinal diseases are ideal candidates for gene therapy because many of the responsible genetic mutations have already been identified.
Read More
Tag: retinal disease
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
